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Abstract
Background—An estimated 13% foreign born persons are living in the United States. Foreign 
born persons are considered at higher risk of under-vaccination and exposure to several vaccine 
preventable diseases pre-migration or during return trips to their birth country. Information on 
vaccination coverage among foreign born populations is limited.
Purpose—To assess adult vaccination coverage disparities among foreign born populations in 
the United States.
Methods—Data from the 2012 National Health Interview Survey were analyzed in 2013. For 
non-influenza vaccines, we calculated the weighted proportion vaccinated. For influenza 
vaccination, we used the Kaplan-Meier survival analysis to assess coverage among individuals 
interviewed during September 2011–June 2012 and vaccinated from August 2011–May 2012.
Results—Overall, unadjusted vaccination coverage among U.S. born respondents was 
significantly higher than that of foreign born respondents: influenza, ≥18 years (40.4% versus 
33.8%); PPV, 18–64 years with high-risk conditions (20.8% versus 13.7%); PPV, ≥65 years 
(62.6% versus 40.5%); tetanus vaccination, ≥18 years (65.0% versus 50.6%); Tdap, ≥18 years 
(15.5% versus 9.3%); hepatitis B, 18–49 years (37.2% versus 28.4%); shingles, ≥60 years (21.3% 
versus 12.0%); and HPV, females 18–26 years (38.7% versus 14.7%). Exceptions were noted for 
hepatitis A vaccination among travelers and hepatitis B vaccination of persons ≥18 years with 
diabetes. Among the foreign born, vaccination coverage was generally lower for non-U.S. citizens, 
recent immigrants, and those interviewed in a language other than English. Foreign born were less 
likely than U.S. born to be vaccinated for pneumococcal (≥65 years), tetanus (≥18 years), Tdap 
(≥18 years), and HPV (women 18–26 years) after adjusting for confounders.
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Conclusions—Vaccination coverage was lower among foreign born adults than those born in the 
U.S. Vaccination coverage varied by immigration status, citizenship, language, and demographic 
characteristics. As the number of foreign born persons residing in the United States increases, it is 
important to consider foreign birth and immigration status when assessing vaccination disparities 
and planning interventions.
Keywords
Adult vaccination; vaccination coverage; foreign born; immigration status; National Health 
Interview Survey (NHIS)
Introduction
Overall, in 2011, an estimated 40 million foreign born persons (13% of the U.S. population) 
were living in the United States, an increase compared with 1970 (5%). 1–3 The foreign born 
are individuals born outside of the United States, Puerto Rico, and other U.S. affiliated areas, 
such as Guam and the Marshall Islands who were not U.S. citizens at birth.1 While foreign 
born populations are spread across the United States, in 2011 more than 25% lived in 
California; an additional 30% lived in New York, Texas, or Florida. The foreign born from 
Latin America was the largest region-of-birth group, accounting for 53% of all foreign born, 
followed by 29% from Asia, 12% from Europe, and 7% from other regions. Most (65%) 
foreign born arrived in the United States before 2000.1
Prevalence of most vaccine-preventable diseases (VPD) in the United States is at or near 
record lows, but VPDs remain endemic in other world regions. Foreign born persons from 
endemic countries and their family members in the United States are at greater risk of 
exposure for some VPDs (e.g., hepatitis A and B, congenital rubella) either pre-migration or 
during return trips to visit friends and family.4–6 Foreign born individuals, particularly those 
from Mexico, have been shown to have lower evidence of protective antibodies for some 
VPDs possibly due to lack of vaccination, lower exposure, and/or waning immunity over 
time (e.g., tetanus, hepatitis B, and varicella). 5, 7–10 The Advisory Committee on 
Immunization Practices (ACIP) recommends vaccinations for adults in the United States to 
prevent VPDs and their sequelae.11 Influenza vaccination is recommended for adults of all 
ages each year; other vaccines target different populations based on age, high-risk medical 
conditions, behavioral risk factors (e.g., injection drug use), occupation, travel, and other 
indications.12–13 Most foreign born originate from countries with different vaccination 
schedules and practices than the United States. Despite great improvements in global 
vaccination coverage in recent years, coverage remains low in many regions.14 Even in the 
United States, adult vaccination coverage remains low for most routinely recommended 
vaccines and well below Healthy People 2020 targets. 12, 13, 15
Analysis of two U.S. national surveys comparing vaccination coverage between foreign born 
children and children of foreign born mothers versus U.S. born children and children of U.S. 
born mothers, respectively, found disparities in vaccination levels of the foreign born for 
some vaccines (e.g., hepatitis B and Haemophilus influenzae type b) and advantages for 
others (e.g., pneumococcal conjugate vaccine and meningococcal conjugate vaccine).6–9, 16 
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Vaccination coverage disparities for foreign born compared to native populations have been 
reported from Canada and several countries in Europe, Africa, and Asia. 17–23 A few studies 
in the United States have reported disparities in some vaccinations among foreign born 
adults at national, state or local levels. 8, 24–27 However, comprehensive information on 
vaccination coverage on that population is limited. The purpose of this study is to examine 
coverage for select routinely-recommended adult vaccinations among the foreign born 
compared with U.S-born individuals, by selected demographic characteristics, to help guide 
development of strategies for improving vaccination coverage among foreign born 
populations. Coverage for influenza; pneumococcal polysaccharide vaccine [PPV]; tetanus 
toxoid–containing vaccines including tetanus and diphtheria toxoid [Td] and tetanus, 
diphtheria and acellular pertussis [Tdap]; hepatitis A [HepA]; hepatitis B [HepB]; herpes 
zoster [shingles]; and human papillomavirus [HPV] vaccines were assessed.
Methods
Data from the 2012 National Health Interview Survey (NHIS) were analyzed in 2013. The 
NHIS is an annual household survey conducted by the National Center for Health Statistics, 
Centers for Disease Control and Prevention (CDC), which collects health information on the 
U.S. civilian, non-institutionalized population. 28 Detailed methods for the NHIS were 
described in other publications.14, 28 In 2012, the final response rate for the sample adult 
core was 61.2%.28 The NHIS has routinely collected influenza and PPV vaccination 
information since 1989. Starting from 2004, HepB vaccination information was collected. 
Staring from 2008, other vaccination information such as HepA, HPV, Shingles, and Td/
Tdap was collected.
Vaccination coverage by foreign born status for influenza, PPV, tetanus-toxoid-containing 
vaccines (Td, Tdap or unknown type) in the past 10 years, HepA, HepB, shingles, and HPV 
vaccines were assessed from coded survey questions on receipt of these vaccines.
Covariates from coded survey questions to measure associations among vaccination 
coverage were selected: U.S. born status, time in the United States, language spoken during 
interview, world region of birth, racial/ethnic status, nativity, and citizenship status. HepA 
vaccination was assessed among those traveling to countries of high or intermediate 
endemicity. Persons with high-risk conditions for pneumococcal vaccination were 
determined by questions in the NHIS and defined as persons with asthma, diabetes, 
cardiovascular disease, liver diseases, kidney diseases, chronic obstructive pulmonary 
disease, emphysema, chronic bronchitis, cancer, and current smokers. Poverty status was 
defined using 2012 poverty thresholds published by the U.S. Census Bureau with below 
poverty defined as a total family income of <$23,492 for a family of four.29
Multivariable logistic regression and predictive marginals were conducted to assess 
vaccination coverage among U.S. born and foreign born adjusted for age, gender, race/
ethnicity, marital status, education, employment status, poverty level, health insurance, 
number of doctor visits in the past year, whether the respondent had a usual place of health 
care, self-reported health status, and region of residence. Adjusted prevalence ratios were 
calculated comparing U.S. born and foreign born.
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SUDAAN statistical software (Research Triangle Institute, Research Triangle Park, NC) was 
used to calculate point estimates and 95% confidence intervals of vaccination coverage.30 
We used SUDAAN generated asymmetric confidence intervals based on a logit 
transformation. For the non-influenza adult vaccination coverage estimates, we used 
weighted percentages. To better assess unadjusted influenza vaccination coverage for the 
2011–12 influenza season, the Kaplan-Meier survival analysis procedure was used to assess 
coverage among individuals interviewed from September 2011 through June 2012 and 
vaccinated during August 2011 through May 2012.31 The Kaplan-Meier has advantages for 
season-specific influenza estimates over other approaches, such as using a full calendar year 
of data, or restricting estimates based on interviews conducted in the postvaccination period 
(e.g. March–June) which does not use all relevant data (31). The Kaplan-Meier approach 
uses all relevant data to maximize precision and to use data collected during the vaccination 
period that likely has more accurate recall of vaccinations.31 To assess adjusted vaccination 
coverage and adjusted prevalence ratios, we used logistic regression and predicted marginal 
modeling comparing US born and foreign born for each selected vaccination. The NHIS was 
approved by Research Ethics Review Board (the ERB number is 2009–16) of the National 
Center for Health Statistics, Centers for Disease Control and Prevention.
Results
Demographic characteristics of the study population are given in Table 1. Of adults ≥18 
years, 82.6% were born in the United States, and 17.4% were foreign born. Among the 
foreign born, 49.3% were from Mexico, Central America or Caribbean Islands, 22.7% from 
Asia, 12.3% from Europe, and 6.0% from South America (Table 1).
Overall, vaccination coverage among U.S.-born respondents was significantly higher than 
that of foreign born respondents (Table 2): influenza ≥18 years (40.4% versus 33.8%); PPV 
18–64 years with high-risk conditions (20.8% versus 13.7%); PPV ≥65 years (62.6% versus 
40.5%); tetanus vaccination ≥18 years (65.0% versus 50.6%); Tdap ≥18 years (15.5% versus 
9.3%); hepatitis B 18–49 years (≥ 3 doses) (37.2% versus 28.4%); shingles ≥60 years 
(21.3% versus 12.0%); and, HPV females 18–26 years (≥ 1 doses) (38.7% versus 14.7%) 
(Table 2). Exceptions were noted for hepatitis A vaccination among travelers and hepatitis B 
vaccination of persons ≥18 years with diabetes (Table 2).
Vaccination coverage was significantly higher for foreign born living in the United States 
<10 years compared with those in the United States ≥10 years for Tdap vaccination (11.8% 
versus 8.7%, respectively), HepB vaccination (18–49 years) (33.7% versus 26.3%) and 
HepB vaccination (≥18 years with diabetes) (49.8% versus 20.6%) (Table 2). Vaccination 
coverage was significantly lower for foreign born with <10 years of residence in the United 
States compared with those with longer residence (≥10 years) for influenza vaccination 
(23.8% versus 36.4%, respectively) and PPV, 18–64 years with high-risk conditions (7.4% 
versus 14.7%) (Table 2). Except for PPV vaccination of adults ≥65 years, vaccination 
coverage among foreign born adults who were U.S. citizens was significantly higher than 
that for foreign born respondents who were not U.S. citizens (p < 0.05) (Table 2).
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Among U.S. born respondents who preferred to be interviewed in a non-English language, 
vaccination coverage was significantly lower for influenza, tetanus, and HPV vaccination for 
females 18–26 years, compared with coverage among those who preferred to be interviewed 
in English (Table 3). Among foreign born, coverage was significantly lower for all 
vaccinations among those who preferred to be interviewed in a language other than English 
compared with those who preferred English for the interview (Table 3).
Among the U.S. born, coverage for most vaccinations was significantly lower for non-
Hispanic blacks and Hispanics compared with non-Hispanic whites (Table 4). Among the 
foreign born, Hispanics had significantly lower coverage for most vaccinations compared 
with non-Hispanic whites, while non-Hispanic blacks had significantly lower vaccination 
coverage only for Td (Table 4). Among all race/ethnic-nativity groups, Hispanic foreign 
born had the lowest coverage for several vaccines, including influenza, Tdap, HepA, HepB 
(18–49 years old) and shingles (Table 4).
Vaccination coverage by foreign birth region varied across vaccines compared with those 
born in United States (Table 5). Except for HepB vaccination (≥18 years with diabetes), 
adult vaccination coverage was significantly lower among those who were born in Mexico, 
Central America or Caribbean Islands, compared with those who were born in the United 
States. Coverage was lower for those born in Europe compared with coverage among those 
born in the United States for PPV and overall tetanus vaccination, but was higher for HepB 
vaccination for adults ≥ 18 years with diabetes (40.4% versus 20.8%, respectively) and 
similar for other vaccines. Among those who were born in Asia, coverage was lower for 
PPV (≥ 65 years), overall tetanus and Tdap vaccinations, and shingles vaccination, but was 
higher for HepB vaccination (≥ 18 years with diabetes) (34.5% versus 20.8%, respectively) 
(Table 5).
After adjusting for confounders, foreign born adults aged ≥65 years were less likely to 
receive pneumococcal vaccination than U.S. born, and foreign born adults aged ≥18 years 
were less likely to receive tetanus or Tdap vaccination than U.S. born (Table 6). Foreign 
born women aged 18–26 years were less likely to receive HPV vaccination than U.S. born 
(Table 6).
Discussion
This is the first comprehensive assessment of vaccination coverage among foreign born 
adults in the United States. Overall, vaccination coverage was generally lower among the 
foreign born compared with U.S born individuals, even after adjusting for confounders for 
pneumococcal, tetanus, Tdap, and HPV. Vaccination coverage for foreign born differed by 
time living in the United States, citizenship status, language used for interview, race/
ethnicity, and birth country/region. Among the foreign born, vaccination coverage was 
generally lower among non U.S. citizens, those interviewed in a language other than 
English, and non-Hispanic blacks or Hispanics compared with U.S. citizens, those 
interviewed in English and non-Hispanic whites. The Hispanic foreign born had the lowest 
coverage for several vaccines. This finding is particularly relevant because the foreign born 
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from Latin America accounts for more than half of all foreign born adults in the United 
States.1–3
Vaccination coverage among foreign born in the United States depends on the vaccinations 
received as children or adults pre-migration, during migration, post-migration, or during 
return visits to their country of origin. Vaccination coverage and immunization schedules 
vary by country and even by regions within countries.11, 14, 32 For example, the adult 
vaccination schedules in Mexico are different compared with the United States (e.g., 
influenza: persons ≥60 years, pregnant women, and persons with risk factors (Mexico) 
versus universal vaccination (U.S.); PPV: persons persons ≥60 years with high-risk 
conditions, and persons ≥65 years versus persons 18–64 years with high-risk conditions and 
persons ≥65 years; Td: all adults (every 10 years) versus all adults (every 10 years); 
Tdap:pregnant women versus persons ≥18 years; HepA:no adult recommendation versus 
persons with high-risk behaviors and persons who traveling to a country of high or 
intermediate endemicity; HepB: no adult recommendation versus persons with high-risk 
behaviors, persons with diabetes, and Health care personnel; HPV:no adult recommendation 
versus persons 18–26 years; and Shingles: no adult recommendation versus persons ≥60 
years 11, 33 The differences between the US and other countries in the schedules of routine 
vaccinations among adults may contribute to differences in the coverage levels of the 
vaccines studied. In most countries, immunization programs have historically focused on 
children.34–36 Depending on their origin, age at arrival, and year of arrival, adult foreign 
born may be likely to have differences in vaccination coverage compared with U.S. born 
populations when they arrive in the United States. 10, 24
After arrival in the United States, many foreign born adults experience socioeconomic, 
cultural, linguistic and other barriers to accessing health care and preventive services, 
including immunizations.1, 2, 37 The percentage of uninsured was higher among non-U.S. 
citizens, recent immigrants, and those with poor/fair English proficiency. 3, 38 Our study 
findings of lower vaccination coverage for non-citizens, recent immigrants, and those 
interviewed in a language other than English are not unexpected. These characteristics are 
closely associated with lower access to care.3 Those populations may also be less aware of 
U.S. adult immunization recommendations. 39
Our finding of disparities in vaccination coverage for non-English speakers has also reported 
previously.40–45 Limited-English proficiency has been reported to be an impediment to 
accessing health services and health promotion programs.40, 44 Disparities in influenza and 
pneumococcal immunizations among older adults have been reported for those speaking 
Spanish at home,40 those with limited English fluency, those who were Hispanic Spanish-
speaking versus Hispanic English speakers41–45 and those not having English as their 
primary language,40–45 independent of many demographic, access-to-care, and other factors.
43
The findings in this report are subject to one limitation. Adult vaccination coverage was self-
reported and therefore might be subject to recall bias. However, self-reported influenza, 
PPV, tetanus, HepA, HepB, shingles and HPV vaccination status among adults have been 
shown to be sensitive and specific for all except tetanus.47–51 This study confirms the low 
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adult vaccination coverage in the United States, and documents significant disparities for 
foreign born populations. Those disparities are even more relevant because immigration is 
projected to become the principal driver of U.S. population growth and racial/ethnic 
diversity.1, 3, 52 Even when no disparities were identified (e.g., HepB), the low overall 
vaccination coverage is more worrisome for some foreign born populations because of their 
higher risk of exposure to certain VPDs.24
Any comprehensive adult vaccination strategy, particularly among the foreign born, needs to 
be tailored to the needs of the target populations and the capacity of public health and health 
care institutions to address their vaccination needs.53, 54 Access to care factors play an 
important role in vaccination uptake.55–58 Routine assessment of patient vaccination 
histories, recommendation, and offer of needed vaccinations should be incorporated into 
routine clinical care of adults.53, 54, 59 Ensuring standing orders are in place to reduce the 
number of missed opportunities of individuals who have already accessed health care system 
and enhancing reminder and recall systems for patients and providers are proven strategies 
to improve adult vaccination coverage.54 Increasing health care providers’ awareness about 
foreign born vaccination disparities and best practices for addressing them is particularly 
important.54
Given the high proportion of the foreign born with limited access to health care in the United 
States, alternative, targeted, outreach strategies have been recommended,60 including 
offering vaccinations at non-traditional settings (e.g., ethnic fairs, migrant camps, 
workplaces). Community leaders, organizations and community health workers serving 
foreign born adults may be empowered to disseminate linguistic and culturally sensitive 
vaccination information. Access to low cost or free vaccinations may be especially important 
for this population because of its limited economic resources60 and high rate of uninsurance. 
All foreign born individuals, irrespective of their immigration status are eligible for public 
health programs providing vaccinations.61–64 However, other factors such as limited local 
health department funding for vaccinations or immigrants’ lack of awareness of their 
eligibility for those programs, may in practice restrict their use.
The Immigration and Nationality Act65 and guidelines from CDC promote vaccinations 
among certain foreign born populations. All foreign citizens applying for permanent resident 
visa while overseas (482,000 in 2011) or adjusting status when already in the United States 
(580,000 in 2011) are required to show proof of having received all required vaccinations or 
otherwise must receive the first dose for each vaccine series.66 Immigration-required 
vaccination, however, does not apply to unauthorized immigrants (11 million in 2011), those 
admitted with temporary worker visas (3.8 million in 2011), and international students and 
exchange visitors (2.3 million in 2011).67 Several provisions of the Affordable Care Act 
(ACA) might improve access to health care services and ACIP recommended vaccinations 
for some immigrants who were previously without health insurance.68 However, 
unauthorized immigrants are excluded from the ACA and several large categories of foreign 
born legal residents have restrictions in their eligibility for the federal Medicaid program.69 
Collaboration with immunization programs in countries of origin for targeted outreach and 
monitoring of migrants would also improve vaccination coverage among the foreign born.
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Currently, some national surveys used in vaccination coverage monitoring collect no or 
limited data related to foreign born persons, limiting assessment disparities in these 
population. Strategies to increase inclusion of the foreign born in surveys include adding or 
expanding migration-related variables on surveys, ensuring data collection instruments are 
available for the main foreign languages spoken in the United States, making translators 
available, and collaborating with leaders and organizations trusted by foreign born 
communities.42, 53–54, 60, 70–71
As the size and race/ethnic diversity of the foreign born population in the in the United 
States continues to increase, the findings in this study indicate that this population will be 
increasingly important to eliminate national adult vaccination disparities.6 Public policy 
makers, immunization programs and health care providers should consider foreign born 
populations in their public health assessment, evaluation and outreach programs that target 
disadvantaged groups.6
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